JPRN-jRCT1090220035
Completed
Phase 3
Multicenter study evaluating safety and the performance of the intracranial stent system (WS-01) for the treatment of intracranial atherosclerotic disease - WS-01
Kobe City Hospital Organization General HospitalNobuyuki Sakai0 sites20 target enrollmentMarch 9, 2010
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kobe City Hospital Organization General HospitalNobuyuki Sakai
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients treated with WS\-01 stent for recurrent stroke attributable to intracranial atherosclerotic disease, refractory to medical treatment, in intracranial vessels
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
WS-01 Investigator-initiated clinical trialJPRN-jRCT1092220031obuyuki Sakai, Kobe City Hospital Organization Kobe City Medical Center General Hospital20
Completed
Not Applicable
Multicenter study to evaluate safety and performance of Geistlich Bio-Graft® for horizontal ridge augmentationridge width insufficient for placement of dental implantsDRKS00006107Geistlich Pharma AG38
Recruiting
Not Applicable
Multicenter clinical study evaluating safety and efficacy of iron chelation therapy in patients with transfusion-induced iron overloadTransfusion-induced iron overloadJPRN-UMIN000002515The National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan100
Active, not recruiting
Phase 1
Safety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fractioEUCTR2014-001971-30-FIovartis Pharma services AG5,000
Active, not recruiting
Phase 1
Safety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fractioHeart failure with reduced ejection fractionMedDRA version: 19.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-001971-30-LTovartis Pharma Services AG5,000